Marianne De Backer - 22 Feb 2025 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Signature
/s/ Vanina de Verneuil, Attorney-In-Fact
Issuer symbol
VIR
Transactions as of
22 Feb 2025
Transactions value $
$-152,408
Form type
4
Filing time
25 Feb 2025, 15:36:01 UTC
Previous filing
12 Jun 2024
Next filing
04 Apr 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Award $0 +240,000 +38.4% $0.000000 865,339 22 Feb 2025 Direct F1
transaction VIR Common Stock Sale $-152,408 -16,122 -1.86% $9.45 849,217 24 Feb 2025 Direct F2
holding VIR Common Stock 53,118 22 Feb 2025 See Footnote F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIR Stock Option (Right to Buy) Award $0 +480,000 $0.000000 480,000 22 Feb 2025 Common Stock 480,000 $9.57 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
F2 Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
F3 The shares are held in the name of the Ureel-De Backer Family Trust, of which the reporting person and her spouse are Trustees.
F4 25% of the shares subject to the stock option vest and become exercisable on February 22, 2026, and the remaining shares vest in 36 equal monthly installments thereafter.